Fintel reports that on May 18, 2026, Freedom Broker upgraded their outlook for Atara Biotherapeutics (NasdaqGS:ATRA) from Sell to Hold. Analyst Price Forecast Suggests 29.49% Upside As of May 14, 2026 ...

The average one-year price target for Atara Biotherapeutics (NasdaqGS:ATRA) has been revised to $11.90 / share. This is an increase of 25.00% from the prior estimate of $9.52 dated April 25, 2026. The ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

This report should not be treated as legitimate news and instead it should be recognized for what it truly is: a sophisticated public relations campaign designed to manipulate public opinion and ...

This past spring, Congress passed a number of important tax provisions that will impact how taxpayers manage their assets and estates. One of particular significance is the American Tax Relief Act of ...

Atara Biotherapeutics (ATRA) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2022. This widely-known consensus ...

What are the allegations? Robbins LLP is Investigating Allegations that Atara Biotherapeutics, Inc. (ATRA) Misled Investors Regarding its Drug Candidate According to the complaint, during the class ...

View Atara Biotherapeutics Inc ATRA stock quote prices, financial information, real-time forecasts, and company news from CNN.